A detailed history of China Universal Asset Management Co., Ltd. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 16,338 shares of SNDX stock, worth $341,954. This represents 0.05% of its overall portfolio holdings.

Number of Shares
16,338
Previous 16,338 -0.0%
Holding current value
$341,954
Previous $389,000 0.26%
% of portfolio
0.05%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$19.71 - $24.57 $163,198 - $203,439
8,280 Added 102.76%
16,338 $389,000
Q4 2023

May 21, 2024

SELL
$11.39 - $21.67 $94,309 - $179,427
-8,280 Reduced 50.68%
8,058 $174,000
Q4 2023

Jan 23, 2024

BUY
$11.39 - $21.67 $71,483 - $136,000
6,276 Added 352.19%
8,058 $174,000
Q3 2023

May 21, 2024

BUY
$14.52 - $21.77 $12,777 - $19,157
880 Added 97.56%
1,782 $25,000
Q3 2023

Oct 30, 2023

BUY
$14.52 - $21.77 $12,777 - $19,157
880 Added 97.56%
1,782 $26,000
Q2 2023

May 21, 2024

SELL
$19.35 - $22.31 $503 - $580
-26 Reduced 2.8%
902 $18,000
Q2 2023

Jul 27, 2023

SELL
$19.35 - $22.31 $503 - $580
-26 Reduced 2.8%
902 $19,000
Q1 2023

May 21, 2024

BUY
$20.66 - $28.98 $6,528 - $9,157
316 Added 51.63%
928 $19,000
Q1 2023

Apr 27, 2023

BUY
$20.66 - $28.98 $6,528 - $9,157
316 Added 51.63%
928 $20,000
Q4 2022

May 21, 2024

SELL
$20.64 - $26.24 $324,584 - $412,650
-15,726 Reduced 96.25%
612 $15,000
Q4 2022

Jan 31, 2023

BUY
$20.64 - $26.24 $1,692 - $2,151
82 Added 15.47%
612 $16,000
Q3 2022

Oct 21, 2022

BUY
$18.51 - $24.79 $9,810 - $13,138
530 New
530 $13,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $1.18B
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.